FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385837687> ?p ?o ?g. }

• W4385837687 abstract "Abstract People with muco-obstructive pulmonary diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) often have acute or chronic respiratory infections that are difficult to treat due in part to the accumulation of hyperconcentrated mucus within the airway. Mucus accumulation and obstruction promote chronic inflammation and infection and reduce therapeutic efficacy. Bacterial aggregates in the form of biofilms exhibit increased resistance to mechanical stressors from the immune response (e.g., phagocytosis) and chemical treatments including antibiotics. Herein, combination treatments designed to disrupt the mechanical properties of biofilms and potentiate antibiotic efficacy are investigated against mucus-grown Pseudomonas aeruginosa biofilms and optimized to 1) alter biofilm viscoelastic properties, 2) increase mucociliary transport rates, and 3) reduce bacterial viability. A disulfide bond reducing agent (tris(2-carboxyethyl)phosphine, TCEP), a surfactant (NP40), a biopolymer (hyaluronic acid, HA), a DNA degradation enzyme (DNase), and an antibiotic (tobramycin) are tested in various combinations to maximize biofilm disruption. The viscoelastic properties of biofilms are quantified with particle tracking microrheology and transport rates are quantified in a mucociliary transport device comprised of fully differentiated primary human bronchial epithelial cells. The combination of the NP40 with hyaluronic acid and tobramycin was the most effective at increasing mucociliary transport rates, decreasing the viscoelastic properties of mucus, and reducing bacterial viability. Multimechanistic targeting of biofilm infections may ultimately result in improved clinical outcomes, and the results of this study may be translated into future in vivo infection models. Author Summary One of the major challenges associated with chronic respiratory infections in cystic fibrosis and chronic obstructive pulmonary disease is difficult to treat biofilms that form in hyperconcentrated mucus. Biofilms are mechanically robust due to an exterior polymeric matrix that protects from the immune response and antibiotics. Antibiotics like tobramycin alone have little impact on the biofilm matrix, but disruption of viscous mucus and the biofilm architecture has previously been shown to improve antibiotic efficacy. Combination treatments must be used to break up mucus and biofilms and simultaneously kill bacteria. The most promising combination in this study includes the surfactant NP40, the biopolymer hyaluronic acid, and the antibiotic tobramycin which together decreased biofilm viscosity, reduced bacterial load, and increased mucociliary transport rates. The results from this study may be translated to an infected animal study for eventual clinical trials." @default.
• W4385837687 created "2023-08-16" @default.
• W4385837687 creator A5013675446 @default.
• W4385837687 creator A5031950927 @default.
• W4385837687 creator A5035071796 @default.
• W4385837687 creator A5044424476 @default.
• W4385837687 creator A5044710952 @default.
• W4385837687 creator A5051247229 @default.
• W4385837687 creator A5083822344 @default.
• W4385837687 date "2023-08-14" @default.
• W4385837687 modified "2023-10-14" @default.
• W4385837687 title "Combination Treatment to Improve Mucociliary Transport of<i>Pseudomonas aeruginosa</i>Biofilms" @default.
• W4385837687 cites W1983052547 @default.
• W4385837687 cites W1996215008 @default.
• W4385837687 cites W2053418292 @default.
• W4385837687 cites W2054934594 @default.
• W4385837687 cites W2058225831 @default.
• W4385837687 cites W2059119804 @default.
• W4385837687 cites W2072790070 @default.
• W4385837687 cites W2075070043 @default.
• W4385837687 cites W2075159143 @default.
• W4385837687 cites W2100287000 @default.
• W4385837687 cites W2114846377 @default.
• W4385837687 cites W2146979979 @default.
• W4385837687 cites W2151819211 @default.
• W4385837687 cites W2153511020 @default.
• W4385837687 cites W2254678862 @default.
• W4385837687 cites W2290216457 @default.
• W4385837687 cites W2315296278 @default.
• W4385837687 cites W2582215292 @default.
• W4385837687 cites W2755985677 @default.
• W4385837687 cites W2794062554 @default.
• W4385837687 cites W2801000977 @default.
• W4385837687 cites W2889620461 @default.
• W4385837687 cites W2890472136 @default.
• W4385837687 cites W2898244852 @default.
• W4385837687 cites W2912140072 @default.
• W4385837687 cites W2915473700 @default.
• W4385837687 cites W2947765278 @default.
• W4385837687 cites W2965168049 @default.
• W4385837687 cites W3003933287 @default.
• W4385837687 cites W3019884735 @default.
• W4385837687 cites W3033877488 @default.
• W4385837687 cites W3081642623 @default.
• W4385837687 cites W3110746711 @default.
• W4385837687 cites W3133924177 @default.
• W4385837687 cites W3192380610 @default.
• W4385837687 cites W3199753407 @default.
• W4385837687 cites W4205538082 @default.
• W4385837687 cites W4206183808 @default.
• W4385837687 cites W4207022651 @default.
• W4385837687 cites W4225392944 @default.
• W4385837687 cites W4226530667 @default.
• W4385837687 cites W4250844377 @default.
• W4385837687 cites W4280587186 @default.
• W4385837687 cites W4281664317 @default.
• W4385837687 cites W4291899723 @default.
• W4385837687 cites W4309958358 @default.
• W4385837687 cites W4317632586 @default.
• W4385837687 doi "https://doi.org/10.1101/2023.08.14.553173" @default.
• W4385837687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37645913" @default.
• W4385837687 hasPublicationYear "2023" @default.
• W4385837687 type Work @default.
• W4385837687 citedByCount "0" @default.
• W4385837687 crossrefType "posted-content" @default.
• W4385837687 hasAuthorship W4385837687A5013675446 @default.
• W4385837687 hasAuthorship W4385837687A5031950927 @default.
• W4385837687 hasAuthorship W4385837687A5035071796 @default.
• W4385837687 hasAuthorship W4385837687A5044424476 @default.
• W4385837687 hasAuthorship W4385837687A5044710952 @default.
• W4385837687 hasAuthorship W4385837687A5051247229 @default.
• W4385837687 hasAuthorship W4385837687A5083822344 @default.
• W4385837687 hasBestOaLocation W43858376871 @default.
• W4385837687 hasConcept C114682108 @default.
• W4385837687 hasConcept C126322002 @default.
• W4385837687 hasConcept C185592680 @default.
• W4385837687 hasConcept C18903297 @default.
• W4385837687 hasConcept C2775832221 @default.
• W4385837687 hasConcept C2777312293 @default.
• W4385837687 hasConcept C2777637488 @default.
• W4385837687 hasConcept C2777714996 @default.
• W4385837687 hasConcept C2778974779 @default.
• W4385837687 hasConcept C501593827 @default.
• W4385837687 hasConcept C523546767 @default.
• W4385837687 hasConcept C54355233 @default.
• W4385837687 hasConcept C58123911 @default.
• W4385837687 hasConcept C71924100 @default.
• W4385837687 hasConcept C86803240 @default.
• W4385837687 hasConcept C89423630 @default.
• W4385837687 hasConceptScore W4385837687C114682108 @default.
• W4385837687 hasConceptScore W4385837687C126322002 @default.
• W4385837687 hasConceptScore W4385837687C185592680 @default.
• W4385837687 hasConceptScore W4385837687C18903297 @default.
• W4385837687 hasConceptScore W4385837687C2775832221 @default.
• W4385837687 hasConceptScore W4385837687C2777312293 @default.
• W4385837687 hasConceptScore W4385837687C2777637488 @default.
• W4385837687 hasConceptScore W4385837687C2777714996 @default.
• W4385837687 hasConceptScore W4385837687C2778974779 @default.
• W4385837687 hasConceptScore W4385837687C501593827 @default.
• W4385837687 hasConceptScore W4385837687C523546767 @default.

• next